Insider Selling: Intersect ENT Inc (XENT) Insider Sells $592,600.00 in Stock

Intersect ENT Inc (NASDAQ:XENT) insider Lisa D. Earnhardt sold 20,000 shares of the business’s stock in a transaction on Monday, October 15th. The stock was sold at an average price of $29.63, for a total value of $592,600.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Lisa D. Earnhardt also recently made the following trade(s):

  • On Monday, September 17th, Lisa D. Earnhardt sold 20,000 shares of Intersect ENT stock. The stock was sold at an average price of $29.14, for a total value of $582,800.00.
  • On Wednesday, August 15th, Lisa D. Earnhardt sold 20,000 shares of Intersect ENT stock. The stock was sold at an average price of $26.51, for a total value of $530,200.00.

NASDAQ XENT opened at $28.08 on Friday. The stock has a market capitalization of $909.98 million, a P/E ratio of -50.14 and a beta of 0.56. Intersect ENT Inc has a 12 month low of $25.15 and a 12 month high of $42.95.

Intersect ENT (NASDAQ:XENT) last released its quarterly earnings data on Wednesday, August 1st. The medical equipment provider reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.03. The business had revenue of $26.30 million during the quarter, compared to the consensus estimate of $28.15 million. Intersect ENT had a negative return on equity of 15.01% and a negative net margin of 17.22%. The firm’s revenue was up 9.6% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.08) earnings per share. On average, equities analysts expect that Intersect ENT Inc will post -0.86 EPS for the current fiscal year.

A number of equities research analysts have recently weighed in on XENT shares. BidaskClub upgraded Intersect ENT from a “hold” rating to a “buy” rating in a research report on Thursday, June 28th. Piper Jaffray Companies dropped their target price on Intersect ENT from $45.00 to $40.00 and set an “overweight” rating for the company in a research report on Wednesday, August 1st. Canaccord Genuity restated a “buy” rating on shares of Intersect ENT in a research report on Wednesday, August 1st. ValuEngine downgraded Intersect ENT from a “buy” rating to a “hold” rating in a research report on Thursday, August 2nd. Finally, BTIG Research restated a “hold” rating on shares of Intersect ENT in a research report on Thursday, August 2nd. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $39.67.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. increased its holdings in Intersect ENT by 19.2% in the second quarter. BlackRock Inc. now owns 2,310,110 shares of the medical equipment provider’s stock valued at $86,515,000 after purchasing an additional 371,831 shares during the last quarter. FMR LLC increased its holdings in Intersect ENT by 34.3% in the second quarter. FMR LLC now owns 1,068,280 shares of the medical equipment provider’s stock valued at $40,007,000 after purchasing an additional 272,880 shares during the last quarter. Renaissance Technologies LLC increased its holdings in Intersect ENT by 2.4% in the second quarter. Renaissance Technologies LLC now owns 458,307 shares of the medical equipment provider’s stock valued at $17,164,000 after purchasing an additional 10,707 shares during the last quarter. OppenheimerFunds Inc. bought a new stake in Intersect ENT in the second quarter valued at about $14,949,000. Finally, Northern Trust Corp increased its holdings in Intersect ENT by 10.7% in the second quarter. Northern Trust Corp now owns 392,794 shares of the medical equipment provider’s stock valued at $14,710,000 after purchasing an additional 37,818 shares during the last quarter. Institutional investors and hedge funds own 90.27% of the company’s stock.

About Intersect ENT

Intersect ENT, Inc, a drug delivery company, researches and develops products for the treatment of patients with ear, nose and throat conditions in the United States. It offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses.

See Also: What are the risks of holding treasury bonds?

Insider Buying and Selling by Quarter for Intersect ENT (NASDAQ:XENT)

Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply